Lab-Grown tumor organoids could guide bladder cancer treatment

NCT ID NCT05024734

Ongoing Disease control Sponsor: Roland Seiler-Blarer Source: ClinicalTrials.gov ↗

First seen Jul 13, 2026 · Last updated Jul 14, 2026 · Updated 1 time

Summary

This trial tests whether lab-grown miniature tumors, called organoids, can help choose the best chemotherapy for people with intermediate-risk bladder cancer. Tumor samples are taken during surgery and grown in the lab. After testing several drugs on the organoids, the most effective one is given directly into the bladder. The goal is to see if this personalized approach is feasible and may reduce the chance of cancer coming back.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Epirubicin, Mitomycin, Gemcitabine, Docetaxel
What this could lead to: If successful, this approach could personalize bladder cancer treatment, reducing recurrence by selecting the most effective drug for each patient.
What could go wrong: This is a small, early-phase trial focused on feasibility, not yet on long-term outcomes. Organoid growth may fail, and drug selection may not improve recurrence rates.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BLADDER CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-invasive bladder urothelial carcinoma urinary bladder carcinoma Urinary Bladder Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BLADDER CANCER NON-MUSCLE INVASIVE

Contacts and locations

Show contact details

Locations

Spitalzentrum Biel/Bienne

Biel, 2501, Switzerland

More trials for these conditions

Other studies related to the condition(s) this trial covers.